Lipids and lactate in human immunodeficiency virus-1-infected pregnancies with or without protease inhibitor-based therapy

Obstetrics and Gynecology

Volumn 110, Issue 2 I, 2007, Pages 391-397

  Livingston, Elizabeth G ^a   Cohn, Susan E ^b   Yang, Yang ^b   Watts, Heather D ^b   Bardeguez, Arlene D ^b   Jones, Theodore B ^b   Smith, Laura M ^b   Umbleja, Triin ^b   McComsey, Grace A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; LACTIC ACID; LAMIVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DELIVERY; DRUG EFFECT; FEMALE; FISHER EXACT TEST; GASTROINTESTINAL SYMPTOM; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KRUSKAL WALLIS TEST; LACTATE BLOOD LEVEL; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PUERPERIUM; SIDE EFFECT; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; MULTICENTER STUDY; NEWBORN; PREGNANCY COMPLICATION; VIROLOGY;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL, HDL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; LACTIC ACID; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PROTEASE INHIBITORS; TRIGLYCERIDES;

EID: 34548460356     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000271210.79340.4c     Document Type: Article

References (18)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
2. Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA 2006;296:844-54.
3. Brizzi P, Tonolo G, Esposito F, Puddu L, Dessole S, Maioli M, et al. Lipoprotein metabolism during normal pregnancy. Am J Obstet Gynecol 1999;181:430-4.
4. Fahraeus L, Larsson-Cohn U, Wallentin L, Fahraeus L, Larsson-Cohn U, Wallentin L. Plasma lipoproteins including high density lipoprotein subfractions during normal pregnancy. Obstet Gynecol 1985;66:468-72.
5. Floridia M, Tamburrini E, Ravizza M, Tibaldi C, Ravagni Probizer MF, Anzidei G, et al. Lipid profile during pregnancy in HIV-infected women. HIV Clin Trials 2006;7:184-93.
6. Gerard Y, Maulin L, Yazdanpanah Y, De La Tribonniere X, Amiel C, Maurage CA, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000;14:2723-30.
7. Mandelbrot L, Kermarrec N, Marcollet A, Lafanechere A, Longuet P, Chosidow D, et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS 2003;17:272-3.
8. Hitti J, Andersen J, McComsey G, Liu T, Melvin A, Smith L, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007;196:331.e1-7.
9. Bairaktari E, Hatzidimou K, Tzallas C, Vini M, Katsaraki A, Tselepis A, et al. Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels. Clin Biochem 2000;33:549-55.
10. Piquard F, Schaefer A, Dellenbach P, Haberey P. Is fetal acidosis in the human fetus maternogenic during labor? A reanalysis. Am J Physiol 1991;261:R1294-9.
11. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and Interventions to reduce perinatal HIV-1 transmission in the United States. Available at: http://www.aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Retrieved May 22, 2007.
12. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International interim report for 1 January 1989 through 1 January 2006. Available at: http://www.apregistry.com/forms/apr_report_106.pdf. Retrieved May 22, 2007.
13. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346:1863-70.
14. Watts DH. Treating HIV during pregnancy: an update on safety issues. Drug Saf 2006;29:467-90.
15. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12:F241-7.
16. Khoury J, Henriksen T, Christophersen B, Tonstad S. Effect of a cholesterol-lowering diet on maternal, cord, and neonatal lipids, and pregnancy outcome: a randomized clinical trial. Am J Obstet Gynecol 2005;193:1292-301.
17. Dann AT, Kenyon AP, Wierzbicki AS, Seed PT, Shennan AH, Tribe RM. Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy. Obstet Gynecol 2006;107:106-14.
18. Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004;36:772-6.